Specific polyclonal antisera to human interferon-~l (HulFN-~I), human interferon-~2 (HulFN-~2) and human lymphoblastoid interferon (HulFN-ctLy Namalwa) have been raised in rabbits and sheep. The antisera raised against HulFN-~I and HulFN-~2 strongly neutralized the antiviral activity of their homologous IFN-~ subtypes, but were less active against the heterologous IFN-~ subtypes and preparations containing mixtures of IFN-~ subtypes, e.g. human leukocyte interferon (HulFN-aLe). Antisera raised against HulFN-aLy Namalwa strongly neutralized the antiviral activity of all IFN-~-containing preparations and showed weak cross-reactivity with human interferon-fl (HulFN-fl). Neither anti-HulFN-~l nor anti-HulFN-~2 could be demonstrated to neutralize the antiviral activity of HulFN-fl. A number of monoclonal antibodies to HulFN-a2 have been prepared and these were found to neutralize HulFN-~2 antiviral activity to varying degrees, but not to neutralize the heterologous subtype HulFN-~ 1, preparations containing mixtures of IFN-~ subtypes or HulFN-fl.
Many polyclonal antisera raised in animals with partially purified human lymphoblastoid or leukocyte interferon alpha (HulFN-aLe or HulFN-~Ly) also neutralize the antiviral activity of human interferon beta (HulFN-fl) because it has been found that these IFN preparations, and in particular preparations of HulFN-aLy, used for immunization contain small amounts of HulFN-fl (Havell et al., 1975; Dalton & Paucker, 1979) . In practice, it has been difficult to remove all traces of HulFN-fl from HulFN-~Le/Ly preparations and therefore we have used highly purified HulFN-~I and HulFN-~2 to immunize rabbits and sheep. In this study, the neutralizing properties of these antisera were compared to those of (i) polyclonal antisera raised against HulFN-aLy (Namalwa) and (ii) a series of monoclonal antibodies prepared against HulFN-c~2.
HulFN-aLy (Namalwa) was generously provided by Wellcome Research Laboratories, Beckenham, U.K. and was greater than 80 ~o pure with respect to interferon protein. HulFN-~ 1 (D) and HulFN-~2 (A) were gifts from Hoffmann-LaRoche (Nutley, N.J., U.S.A.) and The Schering Corporation (Bloomfield, N.J., U.S.A.), respectively. Both these preparations were highly purified and contained greater than 95 ~ interferon protein. Specific polyclonal antisera were raised in animals by injections at 6-weekly intervals of 106 to 107 IU doses of HulFN-c~Ly or HulFN-~2 and 104 to 10 s IU doses of HuIFN-a 1, the first injection being administered with Freund's complete adjuvant and subsequent injections with incomplete Freund's adjuvant. Rabbit antiserum to human fibroblast interferon (HulFN-fl) was raised by immunizing a rabbit with partially purified HulFN-fl derived from the human osteosarcoma cell line MG63 (Biltiau et al., 1977; Meager et al., 1982) .
Purified HulFN-c~Ly (Namalwa) was separated on slab SDS-polyacrylam~de gels (Laemmli, 1970) and IFN-~Ly components with apparent mol. wt. corresponding to (i) 17 000 to 21000 and containing the bulk of IFN-ct subtypes and (ii) 21000 to 27000, containing the few more slowly migrating IFN-~ subtypes, were eluted from the gels with 0.1 ~ SDS. After concentration and extensive dialysis against phosphate-buffered saline (PBS), the two IFN-~Ly fractions were used to prepare polyclonal antisera by immunizing rabbits.
0022-1317/84/0000-6198 $02.00 © 1984 SGM Short communication Monoclonal antibodies to HuIFN-c~2 were prepared by immunizing BALB/c mice with four doses of 106 IU HuIFN-~2 given at 3-weekly intervals, and fusing the splenocytes of one mouse, given an intravenous boost of l0 T IU HuIFN-c~2 3 days previously, to the P3-X63-Ag8 mouse myeloma line. Hybrid myelomas were screened for monoclonal antibodies to HuIFN-~2 by immunoprecipitation using radioiodinated ~ 2SI-labelled HuIFN-~2 prepared by a 30 s exposure of pure HuIFN-c~2 (50 ~tg) to chloramine-T. Briefly, 30 ~tl of culture supernatant from wells containing hybrid myelomas were incub.ated with 20 ~tl 12SI-labelled HuIFN-c~2 (50000 c.p.m.) at 37 °C for 2 h, 20 ~tl of a 1 : 10 dilution of normal mouse serum and 100 ~tl of a 1 : 3 dilution of sheep anti-mouse F(ab')2 added and incubation continued at 37 °C for 30 rain and then 1 to 2 h at 4 °C. Precipitates were removed by centrifugation, washed twice with PBS, and the radioactivity was counted in an LKB gamma counter. Supernatants which gave a signal/noise ratio (counts bound by test supernatants divided by counts bound by P3-X63-Ag8 supernatant) 'greater than 2 indicated the presence of hybrid myelomas secreting monoclonal antibodies to HuIFN-~2, and these cultures were selected and cloned to prepare a series of hybridoma clones that produced monoclonal antibodies to HuIFN-~2. Several of the positive clones were injected into Pristane-treated BALB/c mice to produce ascitic fluids.
Neutralization of the antiviral effect of IFN was carried out as previously described (Ennis & Meager, 1981) . In this study, IFN samples containing approximately 80 laboratory units (LU) were added to microtitre wells containing serial dilutions of antisera or ascitic fluids and incubated for 1 h at 37 °C to allow neutralization to take place. Human HEp2/c cells were then added to form confluent monolayers. The IFN in the wells was diluted in this step to approximately 10 LU/ml (before neutralization); this concentration gave full protection to HEp2/c cells against encephalomyocarditis virus (EMCV) challenge. After overnight incubation at 37 °C the culture fluids were removed and replaced by culture medium containing EMCV (30 p.f.u./cell). The assays were stained with gentian violet after further incubation at 37 °C for 24 h and the endpoints determined by visual examination. The neutralization titre of the antisera, culture supernatants or ascitic fluids was taken as the reciprocal of that dilution leaving 50~ of the cells protected after virus challenge, i.e. the point at which the IFN remaining un-neutralized in the antibodyinterferon mixtures has an antiviral potency of 1 LU/ml (Kawade, 1980) . Sheep H52 anti-HuIFN-~ 1 strongly neutralized the antiviral activity of HuIFN-~ 1 (Table 1) , but neutralized the heterologous subtype HuIFN-~2 and IFN preparations containing mixtures of HuIFN-~ subtypes to a far lesser degree. Conversely, sheep H49 or rabbit 1 antisera to HuIFN-~2 strongly neutralized HuIFN-c~2, but were rather less active against the heterologous HuIFN-a 1 and preparations containing mixtures of HuIFN-c~ subtypes. Sheep H51 and rabbit 2 antisera to HulFN-c~Ly strongly neutralized all IFN-c~-containing preparations, although with some bias to IFN-c~2 which is probably a major component of HuIFN-c~Ly (Namalwa). Whilst the antisera to the individual subtypes, IFN-c~I and IFN-~2, did not neutralize IFN-fl, antisera to HuIFN~Ly showed weak neutralization of this IFN type which increased as the animals became hyperimmune. When HulFN-~Ly was fractionated on reducing SDS-polyacry~amide gels and the bands corresponding approximately to 21K to 27K and 17K to 21K cut out and the eluted IFNs injected into rabbits, the higher molecular weight material produced an antiserum (rabbit 6) which had a more pronounced neutralizing effect on HuIFN-/~ (Table 1 ). The lower mol. wt. material (17K to 21K) containing the majority of IFN-~ subtypes produced an antiserum (rabbit 7) with neutralizing characteristics similar to antisera produced by immunizing animals with unfractionated HuIFN-~Ly. Other antisera to unfractionated HuIFN-c~Ly (Namalwa) have been raised in goats and cynomolgus monkeys (Macacafascicularis) and they also weakly neutralized HuIFN-//(data not shown).
Monoclonal antibodies to IFN-c~2 showed a wide range of neutralizing activity against homologous IFN-c~2 (Table 2 ). MT4/E4 and MT3/B4 were the most strongly neutralizing monoclonal antibodies and were similar to NK2 monoclonal antibody (Secher & Burke, 1980) to IFN-~ in this respect (Whittall et al., 1984) . Other monoclonal antibodies prepared in this study showed intermediate neutralizing activity e.g. 7/8I, 6/3, 8/8, and one monoclonal antibody, MT1/B9 showed no neutralizing effect on IFN-c~2. This non-neutralizing monoclonal antibody did however bind to IFN-~2, although not so strongly as did neutralizing monoclonal antibodies 
Neutralizing titres of ascitic fluids containing monoclonal antibodies to HulFN-e2
Neutralization titres (log10 NU/ml) against * Signal/noise ratio is the 1251 counts bound by a 1/100 dilution of ascitic fluid containing monoclonal antibody to IFN-c~2 divided by the counts bound by an irrelevant (control) culture fluid in immunoprecipitation assays using either xz5I-HulFN-~l or ~251-HulFN-c~2.
]'ND, Not done.
( Table 2 ). Some of the monoclonal antibodies, e.g. MT4/E4, MT3/B4, weakly bound the heterologous IFN-el, but only one, MT4/E4, showed cross-reactive neutralization to IFN-cd (Table  2) . IFN preparations containing mixtures of IFN-e subtypes were poorly neutralized, if at all, by monoclonal antibodies to IFN-~2. None of these monoclonals neutralized HulFN-fl. Some polyclonal antisera raised against purified HulFN-eLe or HulFN-c~Ly suffer the disadvantage that they contain a small proportion of antibodies which neutralize HulFN-fl (Dalton & Paucker, 1979) . In most cases, the cause of this can be traced to small amounts of HulFN-fl which are produced together with a mixture of IFN-~ subtypes from human buffy coats or lymphoblastoid (Namalwa) cells and which survive in part even after purification. An alternative explanation is that there may be sufficient structural similarities between one or more of the IFN-e subtypes and IFN-fl to cause a number of cross-reacting antibodies to be produced which weakly neutralize IFN-fl. This study, however, more strongly suggests the former explanation. Firstly, purified preparations of IFN-el and IFN-~2 failed to induce antibodies which neutralized IFN-fl. Secondly, it was found that the combination of anti-IFNcd and anti-IFN-e2 (Table 1) and an antiserum obtained from Interferon Sciences Inc. (N.J., U.S.A.) raised against monoclonal NK2-Sepharose-purified HulFN-eLe did not neutralize IFN-fl (data not shown). It is therefore unlikely that either individual IFN-e subtypes or purified IFN-e subtype mixtures induce antibodies that cross-react with IFN-fl. Lastly when HulFNeLy was fractionated into two components, the component with the higher apparent mol. wt. (21K to 27K) gave rise to an antiserum that quite strongly neutralized HulFN-fl. We have found that authentic HulFN-fl, when fractionated on SDS-polyacrylamide gels, has a mol. wt. of 21K to 24K, and it was possible that small amounts of IFN-fl were eluted from the gel slices taken as representative of the 21K to 27K IFN-~Ly band. There remains, however, a remote possibility that the I FN-c~Ly components with apparent tool. wt. of 21K to 27K have closer structural similarity to IFN-fl than either IFN-~I or IFN-~2 or IFN-c~Ly components of apparent mol. wt. 17K to 21K and could induce cross-reacting antibody.
Polyclonal antisera to HuIFN-~I and HuIFN-~2 showed greater specificity to their respective homologous IFN-c~ subtypes than to their heterologous IFN-~ subtypes, but some crossreactivity was always demonstrable. In contrast, monoclonal antibodies to IFN-~2 were, with one exception, totally specific for IFN-c~2. The exception, MT4/E4, was able to neutralize IFN-~1, but over 1000-fold less effectively than IFN-~2. This suggests that IFN-~I and IFN-c~2 are sufficiently structurally dissimilar for monoclonal antibodies to discriminate between these two subtypes. Other groups (Staehelin et al., 1981 ; Imai et al., 1982; Adolf et al., 1982) have also reported studies with monoclonal antibodies to HulFN-c~ which indicate the presence of two or more antigenically distinct subsets among the HulFN-~ subtypes. Further, Allen et al. (1982) have shown that NK2 monoclonal antibody binds only six of eight HuIFN-~Ly components. Therefore, while in theory it should be possible to prepare monoclonal antibodies to the more conserved regions of the polypeptides of IFN-c~ subtypes, in practice this has been difficult to achieve. Presumably, the conserved regions of the intact IFN-c~ subtype proteins do not normally contribute to the antigenicity of the molecules. Nevertheless, Arnheiter et al. (1981) have reported the preparation of a mouse monoclonal antibody directed against a synthetic 56-amino acid residue fragment, representative of the conserved region of HuIFN-0d (residues 111 to 166), which bound equally to intact IFN-ctl and IFN-ct2. This monoclonal antibody was however devoid of neutralizing activity.
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